Please assess the completion status of the following clinical trial:

Trial Title: Microbial Resistance of Rifaximin in Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- The inclusion criteria~1. cirrhosis due to HCV infection~2. age 18 to 75 years,~3. experiencing at least one episode of OHE,~4. MELD score ≤ 25~Exclusion Criteria:~1. Patients with neurological or communication problems,~2. hepatocellular carcinoma~3. diabetes mellitus~4. active infection~5. serum creatinine \> 2 mg/dl, Hg \< 8 g/dL, serum Na \< 125 mmol/L or serum K \< 2.5 mmol/L .~6. Patients with previous intake of rifaximin as prophylaxis or any antibiotic within the last month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- interventional (Type: ACTIVE_COMPARATOR): 50 patient take rifaximin plus lactulose for 6 months
- control (Type: PLACEBO_COMPARATOR): 50 patient take lactulose for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).